Theratechnologies (TSE:TH) Sets New 12-Month High - Here's Why

Key Points

• Theratechnologies reached a new 52-week high of C$4.58, maintaining a trading volume of 62,263 shares.
• Despite the high stock price, Jones Trading downgraded Theratechnologies from a "strong-buy" to a "hold" rating.
• The company specializes in addressing the medical needs of HIV patients and has products like EGRIFTA and Trogarzo approved in North America.

Theratechnologies Inc. (TSE:TH - Get Free Report) hit a new 52-week high on Wednesday . The stock traded as high as C$4.58 and last traded at C$4.58, with a volume of 62263 shares changing hands. The stock had previously closed at C$4.53.

Analyst Ratings Changes

Separately, Jones Trading lowered Theratechnologies from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 3rd. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Theratechnologies has an average rating of "Buy".

Theratechnologies Price Performance

The business has a fifty day simple moving average of C$4.43 and a two-hundred day simple moving average of C$3.65. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of -293.92. The stock has a market cap of C$207.83 million, a PE ratio of -23.79, a P/E/G ratio of -8.50 and a beta of 0.26.

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.